Artiva Biotherapeutics, Inc. filed an 8-K with the SEC on October 27, 2026, disclosing that its board of directors approved the discontinuation of AlloNK (AB-101) development on October 22, 2026, and that the company is initiating a process to explore strategic alternatives while implementing a workforce reduction of approximately 94% of its current employee base.

Key Highlights

  • Program halted: The company announced it is "halting all further development of AlloNK (AB-101)," its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate, according to the filing.
  • Workforce reduction: The board approved a plan to reduce the company's workforce by approximately 94% of its current employee base as part of the Wind Down.
  • Completion timeline: The company expects to complete the workforce reduction in the first quarter of 2027 and to incur a significant majority of Wind Down costs in the fourth quarter of 2026.
  • Preliminary cash position: The company reported preliminary cash, cash equivalents, and investments of approximately $319.1 million as of September 30, 2026.
  • Costs not yet estimated: The filing states the company "cannot reasonably estimate the total costs and charges in connection with the Wind Down" at this time.
  • Strategic alternatives: The company is initiating a process to explore strategic alternatives, which the filing describes as intended "to maximize stockholder value."

Artiva Biotherapeutics Discloses AlloNK Wind Down and Strategic Review Details

According to the 8-K filed on NASDAQ:ARTV, the board of directors of Artiva Biotherapeutics, Inc. voted on October 22, 2026 to discontinue development of AlloNK (AB-101), the company's lead NK cell therapy candidate. Alongside that decision, the board approved a Wind Down plan that includes reducing the company's workforce by approximately 94%, with completion of the workforce reduction expected in the first quarter of 2027. The company disclosed that it expects to incur a significant majority of Wind Down-related costs in the fourth quarter of 2026.

The filing notes that costs associated with the Wind Down will relate primarily to contract termination and other costs connected to discontinuing clinical trials, lease-related costs, other existing liabilities and operational closing activities, and costs related to the workforce reduction. The company stated it "cannot reasonably estimate the total costs and charges in connection with the Wind Down" at this time and acknowledged that additional charges or cash expenditures not currently anticipated may arise.

On the financial side, the company disclosed preliminary cash, cash equivalents, and investments of approximately $319.1 million as of September 30, 2026. The filing cautions that this figure is preliminary, has not been audited or reviewed by the company's independent registered public accounting firm, and may change when complete quarterly results are included in the forthcoming Form 10-Q for the quarter ended September 30, 2026. The 8-K was signed by Fred Aslan, M.D., Chief Executive Officer, on October 27, 2026.

What Was Disclosed

Artiva Biotherapeutics filed an 8-K on October 27, 2026, disclosing board approval on October 22, 2026 to halt AlloNK (AB-101) development, reduce its workforce by approximately 94%, and begin a strategic alternatives process, alongside a preliminary cash position of approximately $319.1 million as of September 30, 2026.